Company: BDRX
Filing Date: 2025-04-29
Form Type: POS AM
Source: 0001214659-25-006581
Chunk: 127

Company: Biodexa Pharmaceuticals Plc
Filing Date: 2025-04-29
Form: POS AM
Chunk 127
---
 directors and officers. Except as prohibited by applicable law, these
deeds of indemnity may require the Registrant, among other things, to indemnify its directors and officers for certain expenses, including
attorneys’ fees, judgments, fines and settlement amounts incurred by such directors and officers in any action or proceeding arising
out of their service as a director or officer of the Registrant, or one of its subsidiaries, or arising out of the services provided to
another company or enterprise at the Registrant’s request.

Insofar
as indemnification for liabilities arising under the Securities Act of 1933, as amended, may be permitted to directors, officers or persons
controlling us pursuant to the foregoing provisions, we have been informed that in the opinion of the Securities and Exchange Commission
such indemnification is against public policy as expressed in the Securities Act and is, therefore, unenforceable.

| Item 7. | Recent Sales of Unregistered Securities |

The following information
is furnished with regard to all securities issued by the registrant within the last three years that were not registered under the Securities
Act of 1933, as amended. Unless otherwise indicated below, the issuance of such shares was deemed exempt from registration requirements
of the Securities Act, of 1933, as amended, as such securities were offered and sold outside of the United States to persons who were
neither citizens nor residents of the United States, pursuant to Regulation S, or such sales were exempt from registration under Section
4(2) of Securities Act of 1933, as amended and Rule 506 of Regulation D promulgated thereunder.

On February 15, 2023, we completed the closing of a private placement pursuant to which we sold to certain institutional investors (1) 3,250,000 Ordinary Shares represented by 325 Depositary Shares at $4,640.00 per Depositary Share, (2) 12,931,020 Ordinary Shares represented by 1,293 Depositary Shares, issuable upon the exercise of Series A Warrants issued in the private placement at an exercise price of $5,360.00 per warrant, (3) 19,396,400 Ordinary Shares represented by 1,939 Depositary Shares, issuable upon the exercise of Series B Warrants issued in the private placement at an exercise price of $5,360.00 per warrant, and (4) 62,184,525 Ordinary Shares represented by 6,218 Depositary Shares, iss